Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
2
Bullish
10
Bearish
19
Neutral
3
Bullish
24
Bearish
17
Neutral
1
Bullish
14
Discovery themes featuring this stock
Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh.
Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter.
Medical devices are the primary growth engine: device revenue grew 44% year-on-year in Q3 and 18% over 9M, driven by glucometers which now represent 76% of device revenue, cumulative sales of 16.85 million meters and 2.33 billion strips, indicating scale in consumables and recurring revenue streams.
Pharma/API revenue is stagnating: total pharma revenue declined 3% over 9M and API revenue fell 5% year-on-year, with APIs concentrated in a few molecules (Atorva, Lorata+Des, Monte) and a higher share of sales in Europe and India, while the U.S. share remains low at 3% of quarterly revenue.
Geographic mix is shifting toward domestic demand, with India rising to 64.1% of Q3 revenue and the U.S. contribution contracting; this concentration amplifies domestic opportunity but also raises exposure to India-specific pricing, distribution and regulatory dynamics that management must navigate.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,947 Cr
High Risk
39.6
36.7
-1.1
2.4
64.57
33.44
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockMorepen Laboratories Ltd (MOREPENLAB) is currently trading at 53.88 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh. Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter. Medical devices are the primary growth engine: device revenue grew 44% year-on-year in Q3 and 18% over 9M, driven by glucometers which now represent 76% of device revenue, cumulative sales of 16.85 million meters and 2.33 billion strips, indicating scale in consumables and recurring revenue streams. Pharma/API revenue is stagnating: total pharma revenue declined 3% over 9M and API revenue fell 5% year-on-year, with APIs concentrated in a few molecules (Atorva, Lorata+Des, Monte) and a higher share of sales in Europe and India, while the U.S. share remains low at 3% of quarterly revenue. Geographic mix is shifting toward domestic demand, with India rising to 64.1% of Q3 revenue and the U.S. contribution contracting; this concentration amplifies domestic opportunity but also raises exposure to India-specific pricing, distribution and regulatory dynamics that management must navigate.
Over the past 52 weeks, Morepen Laboratories Ltd has traded between a low of ₹33.44 and a high of ₹64.57. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Morepen Laboratories Ltd has a market capitalization of approximately 2,947.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Morepen Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,947.44 Cr, Morepen Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Morepen Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Morepen Laboratories Ltd is 39.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Morepen said the CDMO mandate is valued at approximately ₹825 crore, also reported as USD 91 million, from a leading global pharma major.
Morepen reported Q4 FY26 gross revenue of ₹472 crore (+22% YoY) and net profit of ₹20 crore (+69% YoY) in its quarterly narrative.
Revenue from operations rose 10.11% year-on-year to Rs 465.85 crore, while consolidated net profit fell 29.33% to Rs 20.31 crore.
It means the USFDA inspection concluded with zero observations recorded in Form 483, indicating no deficiencies were cited during the inspection.
Regulatory/Compliance Filing
Morepen Laboratories informed that its wholly-owned subsidiary has migrated from IFZA to JAFZA and the name changed from "Morepen Labs - FZCO" to "Morepen Labs FZE" effective 2026-07-20; JAFZA issued continuation certificate and trading licence dated 2026-07-23.
Regulatory/Compliance Filing
Morepen Laboratories informs that its wholly owned subsidiary migrated from IFZA to JAFZA and its name changed from "Morepen Labs - FZCO" to "Morepen Labs FZE" effective 2026-07-20.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
53.88 | 2,947 Cr | 39.55 | 2.36 | 0.37 | 5.96 | 7.58 | 4.94 | ||
184.15 | 2,886 Cr | 29.12 | 0.43 | 0.00 | 1.46 | 2.66 | 0.82 | ||
2776.90 | 2,881 Cr | 42.40 | 8.71 | 0.00 | 20.31 | 21.46 | 11.37 | ||
442.00 | 2,699 Cr | — | 3.23 | 0.00 | -2.93 | -2.42 | -0.57 | ||
218.35 | 2,678 Cr | 73.88 | 2.23 | 0.28 | 3.03 | 3.56 | -2.06 | ||
2315.60 | 2,413 Cr | 52.93 | 9.85 | 0.00 | 16.95 | 17.46 | 9.33 | ||
539.95 | 2,377 Cr | 166.58 | 4.84 | 0.00 | 2.91 | 2.79 | — | ||
| Median: 7 Co. | — | 442.00 | 2,699 Cr | 47.66 | 3.23 | 0.00 | 3.03 | 3.56 | 2.88 |
